Notice: This company has been marked as potentially delisted and may not be actively trading. (ANTX) (ANTX) News Today Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesInsider TradesTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Positive Outlook for AN2 Therapeutics: Buy Rating Justified by Strategic Pipeline Advancements and Strong Financial HealthNovember 20, 2024 | markets.businessinsider.comAN2 Therapeutics downgraded to Hold from Buy at TD CowenNovember 18, 2024 | markets.businessinsider.comTD Cowen downgrades AN2 Therapeutics, Inc. (ANTX) to a HoldNovember 18, 2024 | markets.businessinsider.comAN2 Therapeutics Reports Third Quarter 2024 Financial Results, Provides Important EBO-301 Update and Highlights Progress Across Boron Chemistry PipelineNovember 13, 2024 | businesswire.comAN2 Therapeutics (NASDAQ:ANTX) Stock Quotes, Forecast and News SummaryOctober 9, 2024 | benzinga.comUS Marines’s new high-power microwave C-UAS can melt down multiple drones in secondsOctober 4, 2024 | msn.com3 Penny Stocks To Buy With Just $750September 24, 2024 | 247wallst.comMarket Perform Rating Maintained for AN2 Therapeutics Amidst Pipeline Potential and Phase 2 SetbacksSeptember 13, 2024 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: AN2 Therapeutics, Inc. (ANTX) and Roche Holding AG (OtherRHHVF)September 12, 2024 | markets.businessinsider.comANTX Stock Earnings: AN2 Therapeutics Beats EPS for Q2 2024August 13, 2024 | markets.businessinsider.comWhy Is AN2 Therapeutics (ANTX) Stock Down 35% Today?August 9, 2024 | investorplace.comAN2 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business and Scientific HighlightsMay 14, 2024 | businesswire.comMaintaining Caution: AN2 Therapeutics Hold Rating Amidst Epetraborole Trial UncertaintiesApril 9, 2024 | markets.businessinsider.comBuy Rating Affirmed for AN2 Therapeutics Amidst Upcoming Catalysts and Strong Valuation ProspectsApril 2, 2024 | markets.businessinsider.comANTX Stock Earnings: AN2 Therapeutics Beats EPS for Q4 2023March 29, 2024 | markets.businessinsider.comAN2 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business and Scientific HighlightsMarch 28, 2024 | businesswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of AN2 Therapeutics, Inc. - ANTXMarch 11, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of AN2 Therapeutics, Inc. - ANTXMarch 3, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of AN2 Therapeutics, Inc. - ANTXFebruary 24, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of AN2 Therapeutics, Inc. - ANTXFebruary 17, 2024 | markets.businessinsider.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of AN2 Therapeutics, Inc. - ANTXFebruary 15, 2024 | prnewswire.comAN2 Therapeutics just downgraded at Evercore ISI, here's whyFebruary 14, 2024 | realmoney.thestreet.comAN2 Therapeutics shares fall after pausing lung disease study enrollmentFebruary 13, 2024 | reuters.comAN2 Therapeutics just downgraded at Leerink, here's whyFebruary 13, 2024 | realmoney.thestreet.comAN2 Therapeutics, Inc. (ANTX) was downgraded to a Hold Rating at JMP SecuritiesFebruary 12, 2024 | markets.businessinsider.comAN2 Therapeutics Shares Drop 73% After Pausing Enrollment for Epetraborole TrialFebruary 12, 2024 | marketwatch.comJMP Securities gets more bearish on AN2 Therapeutics, downgrades sharesFebruary 12, 2024 | realmoney.thestreet.comAN2 Therapeutics just downgraded at Oppenheimer, here's whyFebruary 12, 2024 | realmoney.thestreet.comAN2 Therapeutics to pause lung disease study enrollmentFebruary 12, 2024 | reuters.comAN2 Therapeutics Stock Plummets On Decision To Pause Enrollment In Epetraborole Phase 2/3 TrialFebruary 12, 2024 | markets.businessinsider.comAN2 to Voluntarily Pause Enrollment in Phase 3 Part of Phase 2/3 Pivotal Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium Avium Complex (MAC) Lung DiseaseFebruary 12, 2024 | finance.yahoo.comAN2 Therapeutics Inc Chief Strategy Officer Kevin Krause Sells 7,417 SharesJanuary 12, 2024 | finance.yahoo.comRecent Price Trend in AN2 Therapeutics, Inc. (ANTX) is Your Friend, Here's WhyJanuary 10, 2024 | finance.yahoo.comThese Biotech Stocks Caught Our Attention - Did You Notice?December 16, 2023 | markets.businessinsider.comOne AN2 Therapeutics Insider Raised Their Stake In The Previous YearNovember 12, 2023 | finance.yahoo.comAN2 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business and Scientific HighlightsNovember 9, 2023 | finance.yahoo.comAN2 Therapeutics, Inc. (ANTX) Is a Great Choice for 'Trend' Investors, Here's WhyNovember 6, 2023 | finance.yahoo.comAN2 Therapeutics Signs License Agreement with the University of Georgia Research Foundation to Develop Novel Boron-Based Therapy for Chagas DiseaseOctober 18, 2023 | finance.yahoo.comPromising Outlook for AN2 Therapeutics, Inc.: Buy Rating Conferred Amid Anticipated Ph.2 Results and Encouraging Epetraborole DevelopmentsOctober 17, 2023 | markets.businessinsider.comAN2 Therapeutics, Inc. (NASDAQ:ANTX) stock most popular amongst individual investors who own 29%, while private equity firms hold 27%October 16, 2023 | finance.yahoo.comAN2 Therapeutics to Present New Data for Epetraborole at IDWeek 2023October 11, 2023 | finance.yahoo.comWhy Wall Street investors are freaking outOctober 4, 2023 | msn.comIs Adagene (ADAG) Outperforming Other Medical Stocks This Year?September 27, 2023 | finance.yahoo.comAN2 Therapeutics Signs Grant Agreement to Discover Novel, Boron Based Therapies for Tuberculosis and MalariaSeptember 26, 2023 | finance.yahoo.comAN2 Therapeutics commences Phase 3 Part of Phase 2/3 Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium complex (MAC) Lung DiseaseSeptember 13, 2023 | finance.yahoo.comHas AN2 Therapeutics (ANTX) Outpaced Other Medical Stocks This Year?September 11, 2023 | finance.yahoo.comHedge Fund and Insider Trading News: George Soros, Ray Dalio, Crispin Odey, Three Arrows Capital (3AC), Cassava Sciences Inc (SAVA), AN2 Therapeutics, Inc. (ANTX), and MoreAugust 25, 2023 | insidermonkey.comAN2 Therapeutics Announces Pricing of $70.0 Million Underwritten Offering of Common StockAugust 16, 2023 | finance.yahoo.comAN2 Therapeutics Reports Second Quarter 2023 Financial Results and Recent HighlightsAugust 10, 2023 | finance.yahoo.comCompanies Like AN2 Therapeutics (NASDAQ:ANTX) Are In A Position To Invest In GrowthJune 14, 2023 | finance.yahoo.com Get (ANTX) News Delivered to You Automatically Sign up to receive the latest news and ratings for ANTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Cackling Kamala hates this company (Ad)Do you want to see one of the most exciting election trades of all time? A trade that could help America become 100% energy independent… Reduce energy costs to virtually zero… And hand investors what could be a stunning return in just a few years’ time? It all has to do with a little known company that is helping to kick off the next great American energy revolution. Before that happens, you need to see the details here. ANTX Media Mentions By Week ANTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ANTX News Sentiment▼0.000.60▲Average Medical News Sentiment ANTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ANTX Articles This Week▼00▲ANTX Articles Average Week Get (ANTX) News Delivered to You Automatically Sign up to receive the latest news and ratings for ANTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies NKTX News Today CKPT News Today SCPH News Today VTYX News Today MCRB News Today NBTX News Today PBYI News Today MNPR News Today GALT News Today TELO News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:ANTX) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding (ANTX) Please log in to your account or sign up in order to add this asset to your watchlist. Share (ANTX) With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
